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Angiopoietins (Ang, also known as Angpt), ligands of the endothe-
lial TEK (Tie2) tyrosine kinase receptor, have been associated with 
vascular remodeling and stabilization signals in angiogenesis (1,2). 
In the blood vascular endothelium, Ang1 exerts agonistic functions 
via increased phoshorylation of Tie2 (3). Both Ang1 and Tie2 are 
essential for the remodeling of a functional blood vessel network 
during embryogenesis (4–6). They also promote various functions 
characteristic of the mature blood vasculature, such as endothelial 
cell survival (7). Until very recently, Ang2 was considered primarily 
as a Tie2 antagonist, being expressed mainly at sites of vascular 
remodeling where it destabilizes the vascular endothelium (8). 
However, evidence is emerging that Ang2 may have different roles 
in the vasculature depending on the context (9,10). The antago-
nistic function of Ang2 is required for normal development of ret-
inal vessels during ocular angiogenesis (11), whereas its Tie2 agonist 
activity is required for normal lymphatic vascular development (12).
Ang2 expression is increased in activated and hypoxic vascular 
endothelial cells in tumors, where it acts as an Ang1 antagonist and 
promotes tumor angiogenesis and growth (13–16). Nasarre et al. 
(17) described an initial transient inhibition of tumor growth and 
angiogenesis in mice with genetically ablated Ang2 (17). The 
blockade of Ang2 with antibodies and peptide-Fc fusion proteins 
results in suppression of primary tumor growth and angiogenesis 
(16,18,19). Notably, elevated circulating Ang2 in patients with 
pancreatic ductal adenocarcinoma was associated with the extent of 
lymphatic metastasis (20). However, very little is known about the 
effects of Ang2 inhibition on metastasis. Because the formation of 
metastases is often crucial for the prognosis of patients, it is impor-
tant to evaluate the effect of Ang2 targeting on tumor cell dis-
semination and the development of metastases. Thus, we 
investigated the effect of Ang2 on tumor progression and metas-
tasis using several different model systems.
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 Background Angiopoietin-2 (Ang2), a ligand for endothelial TEK (Tie2) tyrosine kinase receptor, is induced in hypoxic endo-
thelial cells of tumors, where it promotes tumor angiogenesis and growth. However, the effects of Ang2 on 
tumor lymphangiogenesis and metastasis are poorly characterized.
 Methods We addressed the effect of Ang2 on tumor progression and metastasis using systemic Ang2 overexpression in 
mice carrying tumor xenografts, endothelium-specific overexpression of Ang2 in VEC-tTA/Tet-OS-Ang2 transgenic 
mice implanted with isogenic tumors, and administration of Ang2-blocking antibodies to tumor-bearing immuno-
deficient mice. Fisher’s exact test was used for analysis of metastasis occurrence, and repeated measures one-way 
analysis of variance was used for the analysis of primary tumor growth curves. Unpaired t test was used for all 
other analyses. All statistical tests were two-sided.
 Results Adenoviral expression of Ang2 increased lymph node and lung metastasis in tumor xenografts. The metastatic 
burden in the lungs was increased in transgenic mice in which Ang2 expression was induced specifically in the 
vascular endothelium (tumor burden per grid, VEC-tTA/Tet-OS-Ang2 mice [n = 5] vs control mice [n = 4]: 45.23 vs 
12.26 mm2, difference = 32.67 mm2, 95% confidence interval = 31.87 to 34.07, P < .001). Ang2-blocking antibodies 
reduced lymph node and lung metastasis, as well as tumor lymphangiogenesis, and decreased tumor cell homing 
to the lungs after intravenous injection. In the lung metastases, Ang2 overexpression decreased endothelial integrity, 
whereas the Ang2-blocking antibodies improved endothelial cell–cell junctions and basement membrane contacts of 
metastasis-associated lung capillaries. At the cellular level, the Ang2-blocking antibodies induced the internalization 
of Ang2-Tie2 receptor complexes from endothelial cell–cell junctions in endothelial–tumor cell cocultures.
 Conclusion Our results indicate that blocking Ang2 inhibits metastatic dissemination in part by enhancing the integrity of 
endothelial cell–cell junctions.
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Methods
Mice
Six- to eight-week-old female severe combined immunodeficient 
(SCID) and nu/nu BALB/c mice were obtained from Harlan 
Laboratories (Venray, The Netherlands) and 8- to 12-week-old 
NOD SCID gamma (NSG) mice (stock no. 005557) were obtained 
from the Jackson Laboratory (Bar Harbor, ME). VEC-tTA/Tet-
OS-Ang2 transgenic mice and their littermate controls were used 
in the experiments. The TET-OS-Ang2 responder construct was 
made by polymerase chain reaction cloning of the full-length 
mouse Ang2 open reading frame using the cDNA (GenBank 
NW_001030882.1) downstream of the TET-responsive promoter 
in the pTET-OS-vector [described in (21,22) and Supplementary 
Tables 1 and 2, available online]. Transgenic mouse lines were 
generated by injection of the 2.7-kb expression cassette from the 
vector into fertilized mouse oocytes of the strain FVB/NIH. The 
driver VE-cadherin-tTA [VEC-tTA, (23)] and responder trans-
genic mouse lines were bred together to obtain double transgenic 
VEC-tTA/Tet-OS-Ang2 offspring. To overcome the embryonic 
lethality attributable to endothelial Ang2 overexpression in double 
transgenic embryos [(8) and our unpublished data], Ang2 expres-
sion was repressed during the entire pregnancy. Tetracycline 
(Sigma-Aldrich, St Louis, MO) at 2.0 mg/mL in 5% sucrose was 
added to the drinking water of pregnant females, starting at the 
time of mating and until birth, when Ang2 expression was induced 
by discontinuation of tetracycline administration. Single transgenic 
or wild-type littermates were used as controls for double transgenic 
mice. None of the control mice displayed any obvious phenotype. 
The National Board for Animal Experiments at the Provincial State 
Office of Southern Finland approved all experiments, which were 
performed in accordance with the Finnish legislation regarding the 
humane care and use of laboratory animals.
Cell Culture
The human lung cancer cell line NCI-H460-LNM35 (hereafter 
LNM35) is the previously used and characterized luciferase-
tagged subline of NCI-H460-N15, a human non–small cell carci-
noma of the lung (24); Lewis lung carcinoma (LLC) and HeLa 
cells were purchased from the American Type Culture Collection 
(ATCC, Manassas, VA) and luciferase-tagged B16-F10 melanoma 
cells were obtained from Caliper Life Sciences Inc (Hopkinton, MA) 
(used in passages below 30). LNM35 cells were maintained in 
RPMI-1640 medium supplemented with 2 mM L-glutamine, peni-
cillin (100 U/mL), streptomycin (100 µg/mL), and 10% fetal calf 
serum (PromoCell, Heidelberg, Germany). LLC, HeLa, and lucif-
erase-tagged B16-F10 melanoma cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
2 mM L-glutamine, penicillin (100 U/mL), streptomycin (100 µg/
mL), and 10% fetal calf serum (PromoCell). Human dermal micro-
vascular lymphatic endothelial cells (LECs) and blood microvascular 
endothelial cells (BECs) (PromoCell) were maintained on fibronec-
tin-coated dishes in Endothelial Cell Basal Medium MV (ECBM; 
PromoCell) with growth supplements provided by the manufacturer 
and used in passages 2–6. Vascular endothelial growth factor-C [100 
ng/mL, (25)] was added to the LEC growth medium. For stimula-
tion, 200 ng/µL COMP-Ang1 [Cartilage oligomeric matrix protein-
Ang1, (26)] was added to the endothelial cells for 30 minutes.
Antibody Inhibition of Tumor Growth
Luciferase-tagged LNM35 tumor cells (5 × 106 cells per mouse) 
were implanted into SCID or nu/nu BALB/c mice anesthetized 
with ketamine (Ketaminol; Orion Pharma, Espoo, Finland; or 
Ketalar; Pfizer, New York, NY) and xylazine (Rompun et; Bayer 
Healthcare, Leverkusen, Germany). Once the primary tumor vo-
lumes reached 150–200 mm3, the mice (n = 8–10 per group) were 
randomly assigned to receive an intraperitoneal injection of the 
Ang2-blocking antibody [MEDI3617; MedImmune, Gaithersburg, 
MD; (27)] at a dose of 10 mg/kg, or an equal dose of control human 
immunoglobulin G (hIgG). Thereafter, the intraperitoneal admin-
istration of the antibodies and tumor diameter measurements were 
repeated every second day. At day 16, the primary tumors and 
inguinal regional lymph nodes were excised, weighed, imaged for 
bioluminescence, measured in three dimensions with a digital cal-
iper, photographed, and processed for histological analysis.
Tumor Assays Using AdAng2
Luciferase-tagged LNM35 cells were implanted subcutaneously 
into female SCID mice (n = 9–10 per group), followed by intravenous 
CONTEXTS AND CAVEATS
Prior knowledge
Angiopoietins (Ang) are ligands of the Tie2 tyrosine kinase re-
ceptor and function in vascular remodeling during embryogenesis. 
Ang2 is also overexpressed in hypoxic vascular endothelial cells in 
tumors and promotes tumor angiogenesis and growth. However, 
the mechanisms of Ang2 action in tumor progression and metasta-
sis are poorly known.
Study design
The effects of Ang2 on angiogenesis, tumor growth, and metasta-
sis in lungs were studied by systemic and endothelial cell–specific 
Ang2 overexpression in mice carrying tumor xenografts and in 
transgenic mice implanted with isogenic tumors. The effect of 
Ang2 inhibition was studied with anti-Ang2 antibodies in tumor-
bearing immunodeficient mice.
Contribution
Ang2 increased tumor metastasis at least in part by promoting 
endothelial disruption and increasing tumor cell translocation and 
homing to target organs. Ang2 inhibition also attenuated tumor 
lymphangiogenesis, dissemination of tumor cells via the lymphatic 
vessels, and tumor cell colonization of the lungs.
Implication
Ang2 may promote metastasis in part by disrupting the integrity of 
endothelial cell–cell junctions.
Limitations
Rapidly growing tumors were used in the models. The dose–
response range was not evaluated, and because of the rapid tumor 
growth and treatment schedules, possible adverse effects related 
to the treatment may have gone unnoticed. It remains to be inves-
tigated if the Ang2 antibodies can inhibit metastatic colonization of 
other tissues besides the lungs.
From the Editors
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administration of recombinant in vitro tested AdAng2 (28) or 
AdLacZ, and the primary tumor growth was analyzed as described 
above. At 14 days, D-luciferin (Synchem, Felsberg, Germany) was 
administered intraperitoneally at the dose of 150 mg/kg, followed 
by imaging for bioluminescence 10 minutes after injection. 
Photonic signal intensities were quantified using the Living Image 
software (Xenogen Corporation, Alameda, CA). At 3 weeks, the 
primary tumors and the lymph nodes were excised, imaged for 
bioluminescence, weighed, measured for volume with a digital 
caliper, and processed for histology.
To evaluate lung metastasis, SCID mice (n = 3–6 per group) 
were killed at 4 weeks after the removal of the primary tumors at 
3 weeks, and the lungs were weighed and their bioluminescence 
signal was measured. The bioluminescent signal intensity emitted 
from the metastatic foci was quantified with Living Image Software 
(Xenogen Corporation). The area of region of interest was kept 
constant for all the samples.
Lung Colonization Experiments
SCID or NSG mice (n = 4 in each group) were injected intrave-
nously with adenoviruses encoding angiopoietin-2 (AdAng2) or 
b-galactosidase (AdLacZ) 2 days before systemic inoculation of 
green fluorescent protein (GFP)–tagged LNM35 cells, and lung 
colonization was analyzed 4 days thereafter with fluorescent 
microscopy. To evaluate metastatic growth at later time points, 
B16-F10 or LNM35 cells were implanted intravenously into 
AdAng2- and AdLacZ-treated mice, and the lungs were excised at 
2 (B16-F10) or 3 (LNM35) weeks, weighed, imaged under a 
microscope, and processed for histology. Ang2-blocking antibody 
(10 mg/kg) or an equal amount of hIgG were administered intra-
venously into the mice every second day starting at 
4 days before systemic injection of the GFP- or luciferase-tagged 
LNM35 cells. The lungs of the mice injected with fluorescently 
tagged tumor cells were analyzed 8 days after tumor cell inoculation 
by microscopy (Leica MZFLIII, Leica Microsystems, Vienna, 
Austria). The homing of luciferase-positive LNM35 tumor cells 
into the lungs of mice treated with Ang2-blocking antibodies or 
hIgG was evaluated by bioluminescence imaging ex vivo at 5 days. 
The extent of lung colonization of systemically administered B16-
F10 cells in Ang2-blocking antibody vs hIgG-treated mice was 
assessed at 2 weeks, as described above.
In experiments using the inducible transgenic mouse model, 
B16-F10 melanoma cells (1 × 105 cells) were inoculated intrave-
nously into the conditionally transgenic Ang2 mice and their litter-
mate controls, and the lungs were analyzed 3 weeks after the 
implantation.
Transmission Electron Microscopy
Lung specimens containing melanoma cell colonies from Ang2-
overexpressing, wild-type C57Bl/6J, Ang2-blocking antibody-treated, 
and human serum albumin (HSA) control NSG mice (three mice 
per group) were fixed in 1% glutaraldehyde and 4% formaldehyde 
in 0.1 M phosphate buffer, pH 7.4, postfixed in 1% osmium 
tetroxide, dehydrated in acetone, and embedded in Epon LX112 
(Ladd Research Industries, Williston, VT). Sections of 1.0 µm 
were stained with toluidine blue for histological analysis, and 80-
nm sections were cut with a Leica Ultracut UCT microtome 
(Leica Microsystems, Vienna, Austria) At least three specimens 
from each mouse were examined using a Philips CM100 transmis-
sion electron microscope. Metastasis-associated capillaries, the 
extent of endothelial cell attachment from the basement mem-
brane, and the morphology of endothelial cell–cell junctions were 
assessed and quantified from the samples. Images were captured 
with a Morada CCD camera (Olympus Soft Imaging Solutions 
GMBH, Munster, Germany).
Retinal Angiogenesis Assay
For the retina experiments, the Naval Medical Research Institute 
(NMRI) pups (n = 3–4 per group) were subcutaneously injected 
with 30 mg/kg of Ang2-blocking antibody or hIgG during postna-
tal day (P)0–P4, killed on P5, and the eyes were collected for 
analysis. Blood vessels in the retinas were visualized using biotinyl-
ated Griffonia simplicifolia lectin (Vector Laboratories, Burlingame, 
CA), followed by immunostaining. The following primary anti-
bodies were used: rat anti-mouse Tie2 (TEK4; eBiosciences, San 
Diego, CA; 1:200) and rabbit anti-mouse neural/glial antigen 2 
(NG2, MAB5384; Millipore, Billerica, MA; 1:1000). The primary 
antibodies were detected with the appropriate Alexa secondary 
antibody conjugates (Molecular Probes, Invitrogen, Carlsbad, 
CA). The samples were analyzed with a confocal microscope (Zeiss 
LSM 5 Duo (Carl Zeiss AG, Oberkochen, Germany), objectives 
×10 with NA 0.45, oil objectives ×40 with NA 1.3 and ×63 with NA 
1.4) by using multichannel scanning in frame mode. The pinhole 
diameter was set at one Airy unit for detection of the Alexa 488 
signal and was adjusted for identical optical slice thickness for the 
fluorochromes emitting at higher wavelengths. Three-dimensional 
projections were digitally reconstructed from confocal z-stacks. 
Colocalization of signals was assessed from single confocal optical 
sections. Images of whole retinas were acquired using tile scanning 
using a pinhole diameter greater than three Airy units.
Immunohistochemical Staining
Five-to seven-micrometer sections of paraffin-embedded tissue or 
frozen sections were immunostained with monoclonal antibodies 
against platelet endothelial cell adhesion molecule 1[PECAM-1, 
also known as cluster of differentiation 31 (CD31); BD Biosciences, 
San Diego, CA; dilution 1:500], lymphatic vessel endothelial hyal-
uronan receptor-1 (LYVE-1) (29), neural/glial antigen 2 (NG-2; 
MAB5384; Millipore; dilution 1:300), or laminin (NeoMarkers, 
Fremont, CA; dilution 1:500). The occurrence of metastatic 
LNM35 foci in lymph nodes was detected using anti-cytokeratin 7 
antibodies (Millipore; dilution 1:200). The primary antibodies were 
detected with the Tyramide Signal Amplification detection method 
(PerkinElmer Life Sciences, Waltham, MA) according to manufac-
turer instructions or using fluorescently conjugated secondary anti-
bodies (Molecular Probes, Invitrogen; dilution 1:500 for 1 hour). 
Immunofluorescent staining to detect pimonidazole adducts was 
done with the HypoxyProbe-1 Plus Kit as instructed by the manu-
facturer (Natural Pharmacia International, Burlington, MA).
Cell Staining
All cells were fixed for 10 minutes in 4% paraformaldehyde (PFA) 
phosphate buffered saline (PBS), permeabilized 3 minutes with 
0.1% Triton X-100 in PBS, blocked 5 minutes in 1% bovine 
464   Articles | JNCI Vol. 104, Issue 6  | March 21, 2012
serum albumin (BSA) PBS, and incubated with primary antibodies 
against Tie1 (dilution 1:100), phosphorylated Tie2 (dilution 
1:100), Tie2 (dilution 1:100) and Ang2 (dilution 1:50) (all from 
R&D Systems, Minneapolis, MN), VE-cadherin (BD Biosciences; 
dilution 1:100), phosphorylated endothelial nitric oxide synthase 
(pS1177; Cell Signaling Technology Inc, Danvers, MA; dilution 
1:50), or a tight junction marker ZO-1 (Invitrogen; dilution 1:200), 
in 1% BSA PBS 30 minutes at room temperature. The cells were 
then incubated with secondary antibodies (Molecular Probes, 
Invitrogen; dilutions 1:300) 30 minutes at room temperature. All 
experiments were repeated at least twice with similar results.
Endothelial–Tumor Cell Coculture
BECs transfected with Tie2-GFP (30) retrovirus were cultured on 
fibronectin-coated Transwell filters (0.4 mm pore size) overnight, 
after which the filters were transferred to new 24-well plates with 
or without overnight cultures of LNM35 in the lower compart-
ment (31). The cells were grown in endothelial cell medium for 
48 hours in the presence or absence of the Ang2-blocking antibody 
(2 µg/mL), after which BECs were fixed and used for immunoflu-
orescence staining.
Image Analysis
Bright field sections were viewed with a Leica DM LB microscope 
(Leica Microsystems GmbH, Wetzlar, Germany), and images 
were captured with a Penguin Pro 600es color camera (Pixera 
Corporation, Santa Clara, CA). Immunofluorescent images were 
captured with a Zeiss digital Axiocam camera connected to a 
Zeiss Axioplan 2 microscope (Carl Zeiss AG, Oberkochen, 
Germany). Confocal images were captured using laser scanning 
confocal microscopes Zeiss LSM 510 Meta, Zeiss LSM 5 Duo 
(Carl Zeiss AG), and Olympus FluorView FV1000 (Olympus, 
Tokyo, Japan).
At least five tumors were examined in each experimental group, 
and images from three distinct areas characterized by the mean 
representative density of vessels were captured from each tumor 
under evaluation. The image quantification was carried out using 
ImageJ software (The National Institutes of Health, Bethesda, 
MD).
Ang2 Small Interfering RNA (siRNA) Experiments
Sixty percent confluent overnight cultures of BECs expressing the 
previously characterized Tie2-GFP retrovirus vector (24) were 
transfected with siRNA targeted against human Ang2 (Santa Cruz, 
CA; sc-39305) or with control siRNA (Santa Cruz; sc-37007) using 
Oligofectamine (Invitrogen) and analyzed 48 hours later.
Analysis of Internalization of Cell Surface–Bound Anti-
Ang2 antibody
LECs transfected with Tie2-GFP lentivirus were incubated in 
ECBM with anti-Ang2 antibody or control hIgG (2 µg/mL) on ice 
for 40 minutes following 30 minutes incubation on ice or at 37°C 
to induce the antibody uptake. Cells were either fixed with 4% 
PFA PBS or subjected to acid wash (2 mM glycine in Dulbecco, 
pH 2.0) for 15 minutes to remove the plasma membrane–bound 
antibodies and then fixed. For immunofluorescence staining, cells 
were permeabilized for 5 minutes with 0.1% Triton X-100 in PBS.
In Vitro Detection of Adenoviral Expression
To assess the expression of the adenoviral vector encoded constructs, 
HeLa cells were treated with DMEM starvation medium 30 minutes 
and transfected for 2 hours with adenoviruses expressing Ang2 
(AdAng2) or ß-galactosidase (AdLacZ) (100 MOI). The cells were 
incubated in complete DMEM for 2 days, starved for 40 minutes in 
methionine- and cysteine-free Eagle’s Minimum Essential Medium, 
and metabolically labeled in this medium supplemented with [35S]
methionine/[35S]cysteine (Amersham Biosciences and GE Healthcare, 
Waukesha, WI) at 100 µCi/mL for 10 hours. Conditioned medium 
was then harvested and cleared of particulate material by centrifu-
gation. Proteins were immunoprecipitated with a monoclonal 
antibody against the FLAG tag (Sigma-Aldrich; dilution 1:100) in 
the AdAng2 construct. The antigen–antibody complexes were in-
cubated with protein G sepharose (Amersham Biosciences), sub-
jected to sodium dodecyl sulfate–polyacrylamide (SDS–PAGE) gel 
electrophoresis and visualized with autoradiography.
Construction of Plasmids and Production of Recombinant 
Adeno-Associated Virus (AAV) Vectors
A 1965-bp fragment comprising the mouse Tie2 extracellular 
domain (mTie2-ECD) coding region was obtained from the 
mTEK plasmid (32), digested with EcoRI and BglII, and inserted 
into the pVK1 plasmid. The DNA fragment coding for a VSV tag 
was synthesized, digested with BglII and MluI, and inserted into 
the mTie2-ECD construct, followed by introduction of the Kozak 
consensus sequence (33). The mTie2-ECD-VSV fragment was 
then inserted into a psubCMV-WPRE rAAV expression vector 
(34). A plasmid coding for mouse Tie2-ECD fused to a FLAG tag 
was also constructed. The fragment coding for a FLAG sequence 
was synthesized, digested with BglII and MluI, and inserted into 
the mTie2-ECD-psubCMV-WPRE plasmid. The recombinant 
AAVs of serotype 9 were produced as described previously (35), 
with the exception that the helper plasmid p5E18-VP2/9 was used 
instead of p5E18-VP2/8 (36). The primer sequences and plasmid 
constructs are represented in Supplementary Tables 1 and 3 (avail-
able online).
Confirmation of AAV Expression by Immunoprecipitation 
and Immunoblotting
AAV9-sTie2-ECD-FLAG or AAV9-sTie2-ECD-VSV vector, or 
AAV-HSA as a negative control, was injected into the tibialis 
anterior muscles of 6- to 8-week-old C57Bl/6 mice (n = 5 in each 
group, at the dose of 5 × 1011 to 1 × 1012 virus particles [vp] per 
mouse) anesthetized with the mixture of Ketalar (Pfizer) and 
Rompun vet (Bayer Healthcare). Expression of the soluble form 
of Tie2 was confirmed in blood samples taken 2 weeks after the 
injections. For this, 10-µL samples of serum from each mouse of 
the same group was pooled and incubated with anti-VSV or anti-
FLAG antibodies (Sigma-Aldrich). Proteins were immunoprecipi-
tated with protein G sepharose (Amersham Biosciences), followed 
by separation by 10% SDS–PAGE, and transferred to a nitrocel-
lulose membrane. The membrane was incubated with anti-Tie2 
antibodies (R&D Systems), biotinylated anti-goat secondary anti-
body (Dako, Glostrup, Denmark; dilution 1:2500 for 30 minutes), 
followed by streptavidin–biotin horseradish peroxidase conjugate 
(Amersham Biosciences; dilution 1:8000 for 20 minutes). The 
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Figure 1. Effect of Ang2 on LNM35 primary tumor growth and vascu-
larization. A) Representative images and quantification of biolumines-
cence of LNM35 tumors in AdAng2- and AdLacZ-treated mice at 14 
days after implantation, AdAng2 (n = 10) vs AdLacZ (n = 9) mice. 
Student’s t test. B) Growth curves of the tumors in (A). Repeated 
measures one-way analysis of variance. C and D) Representative im-
munohistochemical images of CD31- and LYVE-1-stained tumor sec-
tions. Samples from at least five mice from both groups were 
quantified. Quantification of CD31- and LYVE-1-positive vessel den-
sities. Student’s t test. Error bars = 95% confidence intervals. Scale bar 
in (A), 10 mm; in (C and D), 200 µm. *P < .05. All statistical tests were 
two-sided. Ang2 = Angiopoietin-2; CD31 = cluster of differentiation 31; 
LacZ = b-galactosidase; LYVE-1 = lymphatic vessel endothelial hyaluro-
nan receptor-1; p/s/cm2/sr = photons/s/cm2/steradian.
proteins were then detected by enhanced chemiluminescence by 
using the SuperSignal West Femto Maximum Sensitivity Substrate 
kit (Thermo Scientific, Rockford, IL).
In Vivo Tumor Assays Using Recombinant AAVs
AAV9-sTie2-ECD or AAV9-HSA was injected intravenously 
into the lateral tail vein of 6- to 8-week-old female nu/nu 
BALB/c mice (n = 14 in both groups) at a dose of 5 × 1011 to 
1 × 1012 vp per mouse, 3 weeks before implantation of LNM35 
cells. The expression of the soluble form of Tie2 was confirmed 
as described above. LNM35 cells were then implanted subcuta-
neously into both abdominal flanks of the mice. Once the 
tumors became readily detectable during the first few days, 
tumor growth was monitored every second day with measure-
ments using a digital caliper, and the volumes were calculated as 
described below. For labeling of hypoxic regions within the 
tumors, pimonidazole (60 mg/kg; Natural Pharmacia 
International, Burlington, MA) was injected intravenously 
under anesthesia 1 hour before killing. At the endpoint, the 
mice were killed and tumors were excised and processed for 
histology.
Statistical Analysis
Statistical analysis was performed with the unpaired t test. Fisher 
exact test was used for the statistical analysis of metastasis occurrence 
and repeated measures one-way analysis of variance was used for 
the analysis of primary tumor growth curves. All statistical tests 
were two-sided. The values are expressed as means ± 95% confi-
dence interval (CI) in the figures, and as means with the difference 
of means and 95% confidence intervals in the text. Differences 
were considered statistically significant at P less than .05.
Results
The Effect of Ang2 Overexpression on Metastasis of Human 
Lung Carcinoma Xenografts
AdAng2 promoted primary LNM35 human lung carcinoma tumor 
growth when compared with AdLacZ. This increased growth was 
observed as enhanced bioluminescence of the tumors in AdAng2-
transfected mice (AdAng2 [n = 10] vs AdLacZ [n = 9] mice: 25.46 × 105 
vs 10.61 × 105 photons/s/cm2/sr; difference = 14.85 × 105 photons/
s/cm2/sr, 95% CI = 6.51 × 105 to 23.19 × 105 photons/s/cm2/sr, 
P = .002; Figure 1, A) and as an increase in tumor volume (AdAng2 
466   Articles | JNCI Vol. 104, Issue 6  | March 21, 2012
[n = 10] vs AdLacZ [n = 9] mice: 797 vs 528 mm3 at day 14; difference = 
269 mm3, 95% CI = 170 to 371 mm3, n = 9, P < .001; Figure 1, B). 
AdAng2 expression was also associated with an increase in the 
density of tumor blood vessels (AdAng2 [n = 5] vs AdLacZ [n = 6] 
mice: 68.43 vs 48.85 vessels per grid; difference = 19.58 vessels per 
grid, 95% CI = 0.09 to 39.07 vessels per grid, P = .049; Figure 1, C) 
and lymphatic vessels (AdAng2 [n = 5] vs AdLacZ [n = 6] mice: 18.13 
vs 12.67 vessels per grid; difference = 5.46 vessels per grid, 95% 
CI = 1.11 to 9.81 vessels per grid, P = .019; Figure 1, D). Importantly, 
AdAng2 increased regional lymph node metastasis when measured 
3 weeks after subcutaneous implantation of LNM35 tumor cells 
(Figure 2, A and D, and data not shown, a trend for increased 
bioluminescent signal intensity from lymph nodes in AdAng2 mice 
ex vivo, AdAng2 vs AdLacZ mice: 6.36 × 107 vs 1.02 × 107 
Figure 2. Effect of Ang2 expression on lung 
metastasis. A) Representative biolumines-
cent images of inguinal lymph nodes 3 
weeks after subcutaneous implantation of 
LNM35 tumors. B) Representative ex vivo 
bioluminescent images of lungs at 7 weeks 
after implantation of luciferase-positive 
LNM35 cells into the abdominal subcutis 
(4 weeks after the excision of the primary 
tumor). C) Representative images of hema-
toxylin- and eosin-stained lung sections 
from AdAng2- and AdLacZ-treated mice 
killed 3 weeks after systemic LNM35 inocu-
lation. D) analysis of lymph node volumes, 
represented in (A), AdAng2 (n = 10) vs 
AdLacZ (n = 9) mice. E) Analysis of LNM35 
metastatic foci per grid in histological sec-
tions from the experiment in (C), n = 4 in 
both groups. F) Quantification of lung 
weights 7 weeks after s.c. tumor cell implan-
tation of LNM35 cells and 3 weeks after i.v. 
of the tumor cells, AdAng2 (n = 3) vs AdLacZ 
(n = 6) mice and n = 4 in both groups, respec-
tively. G) Representative lungs with B16-F10 
metastases in AdAng2- vs AdLacZ-treated 
mice at 2 weeks after intravenous adminis-
tration of tumor cells. H) Bioluminescent 
images of lungs with B16-F10 metastatic foci. 
I and J) Analysis of B16-F10 lung metastasis 
foci per grid (AdAng2 vs AdLacZ) and 
lung weights, n = 4 in both groups. K) 
Quantification of B16-F10 melanoma tumor 
burden in conditionally transgenic Ang2 
mice (VEC-tTA/Tet-OS-Ang2 mice) and con-
trols, VEC-tTA/Tet-OS-Ang2 mice [n = 5], 
and control [n = 4] mice. All statistical tests 
were two-sided Student’s t tests. Asterisks 
indicate statistically significant differences. 
Error bars = 95% confidence intervals. Scale 
bar in (A) and (G), 2 mm; in (B), 5 mm; in (C), 
1 mm (left panel); 100 µm (right panel). 
Ang2 = Angiopoietin-2; LacZ = b-galactosidase; 
i.v. = intravenous; s.c. = subcutaneous;  
p/s/cm2/sr = photons/s/cm2/steradian; VEC-
tTA/Tet-OS-Ang2 = VE-cadherin-tTA/Tet-OS-
Ang2 transgenic mouse.
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photons/s/cm2/sr), reflected as a statistically significant increase of 
inguinal lymph node volume in AdAng2-treated mice (AdAng2 [n = 
10] vs AdLacZ [n = 9] mice: 19.82 vs 5.96 mm3; difference = 13.86 
mm3, 95% CI = 2.24 to 25.49 mm3, P = .022; Figure 2, D).
AdAng2 also promoted metastasis of the LNM35 tumor cells 
into the lungs, as indicated by a statistically significant increase in 
lung weight (AdAng2 [n = 3] vs AdLacZ [n = 6] mice: 0.59 vs 0.28 g: 
difference = 0.31 g, 95% CI = 0.05 to 0.57 g, P = .027; Figure 2, F), 
and a trend for increased bioluminescence signal in the lungs of 
AdAng2 expressing vs control mice (AdAng2 2.45 × 107 vs AdLacZ 
0.33 × 107 photons/s/cm2/sr; Figure 2, B), both measured at 
4 weeks after the excision of the primary tumor. Furthermore, Ang2 
enhanced the establishment and growth of tumor cell colonies in 
the lungs at 3 weeks after the intravenous injection of LNM35 cells 
into immunodeficient NSG mice as evaluated by the lung weight 
(AdAng2 vs AdLacZ mice: 0.64 vs 0.42 g: difference = 0.21 g, 95% 
CI = 0.04 to 0.38 g, P = .02; Figure 2, F) and the density of metas-
tastic foci in lungs (AdAng2 [n = 4] vs AdLacZ [n = 4] samples: 15.6 
vs 9.7 metastatic foci per grid; difference = 6.1, 95% CI = 2.8 to 9.3, 
P = .004; Figure 2, C and E). Similar results were obtained when 
B16-F10 melanoma cells were used (Figure 2, G–J, metastatic foci 
per grid in lungs of AdAng2- vs AdLacZ-treated mice [n = 4 in 
both groups]: 47.1 vs 20.4; difference = 26.6, 95% CI = 11.2 to 
42.1, P = .006; Figure 2, I).
Expression of Ang2 is induced in the endothelium of hypoxic 
tumor vessels (15). We analyzed the effect of endothelial Ang2 
overexpression on tumor cell metastasis in a conditionally Ang2-
overexpressing transgenic mouse model (VEC-tTA/Tet-OS-
Ang2), in which the VE-cadherin-tTA construct drives Ang2 
expression after the discontinuation of tetracycline administration. 
Isogenic B16-F10 cells were injected into the tail vein of Ang2-
overexpressing mice, and their littermate controls and the lungs 
were collected 3 weeks after injections. The total lung colony bur-
den was statistically significantly increased in Ang2-overexpressing 
mice when compared with the controls (VEC-tTA/Tet-OS-Ang2 
[n = 5] vs control [n = 4] mice: 45.23 vs 12.26 mm2; difference 32.67 
mm2, 95 % CI = 31.87 to 34.07, P < .001; Figure 2, K).
The Effect of Ang2-Blocking Antibody on Inhibition of 
Lymphatic and Lung Metastasis
To assess the role of endogenous Ang2 produced by endothelial 
cells of tumor vessels, we used an Ang2-blocking antibody (27). 
Luciferase-tagged LNM35 cells were implanted subcutaneously into 
nu/nu and SCID mice, and after tumor establishment, the mice were 
randomly assigned to receive 10 mg/kg doses of Ang2-blocking 
antibody or control hIgG every other day. The Ang2-blocking 
antibody statistically significantly inhibited primary tumor growth 
(Figure 3, A and B, tumor weight at excision in nu/nu mice: in 
Ang2-blocking vs in hIgG group, n = 8 for both groups, 0.84 vs 
1.36 g; difference = 0.52 g, 95% CI = 0.81 to 0.23 g, P = .002; in 
SCID mice: in Ang2-blocking group vs in hIgG control mice, n = 10 
in both groups, 0.81 vs 1.09 g; difference = 0.28 g, 95 % CI = 0.003 
to 0.54 g, P = .048) as well as tumor angiogenesis (Ang2-blocking 
antibody vs hIgG group, n = 8 in both groups, 17.85 vs 21.45 
CD31-positive vessels/grid; difference = 3.60, 95% CI = 0.70 to 
6.50, P = .019; Figure 3, C and D and Supplementary Figure 1, 
available online), as expected on the basis of previously published data 
Figure 3. Ang2-blocking antibodies inhibit primary tumor growth, an-
giogenesis, and lymphangiogenesis. A) Growth curves of LNM35 primary 
tumors in nu/nu mice treated with the Ang2-blocking antibodies or hIgG 
control, n = 8 in both groups. One-way analysis of variance. B) Tumor 
weights at excision 16 days after implantation, P = .002. Student’s t test. C) 
Representative immunohistochemical images of LYVE-1- and CD31-
stained tumor sections. D) Quantification of densities and area fractions of 
Lyve-1-positive lymphatic vessels and of CD31-positive blood vessels from 
at least five histological sections, P = .013 and .019, respectively. Student’s 
t test. All statistical tests were two-sided. *P < .05. Error bars = 95% CI. 
Anti-Ang2 = angiopoietin-2-blocking antibody; CD31 = cluster of differenti-
ation 31; hIgG = human immunoglobulin G; LYVE-1 = lymphatic vessel 
endothelial hyaluronan receptor-1. Scale bar, 120 µm.
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using Ang2-blocking antibodies in various tumor xenografts (16,19). 
The Ang2-blocking antibody appeared to induce regression of the 
endothelium, whereas pericytes and basement membrane structures 
were detected even after anti-Ang2 antibody treatment 
(Supplementary Figure 2, available online). Importantly, the Ang2-
blocking antibody also attenuated tumor lymphangiogenesis (Ang2-
blocking group vs hIgG control group, n = 8 in both groups, 11.95 vs 
15.37 LYVE-1-positive vessels per grid; difference = 3.42, 95% CI = 
0.85 to 5.98, P = .013; Figure 3, C and D).
Similar to the Ang2-blocking antibodies, administration of the 
extracellular domain of Tie2 that binds both Ang1 and Ang2 via an 
AAV vector resulted in an inhibition of LNM35 tumor growth and 
angiogenesis (Supplementary Figure 3, available online), consis-
tently with the previously reported results (37).
To analyze the effect of Ang2-blocking antibodies on tumor 
metastasis, we measured tumor cell dissemination into the regional 
(inguinal) lymph nodes. The rate of lymph node metastasis and 
lymph node weight at the time of excision of primary tumors were 
decreased in SCID mice treated with the Ang2-blocking anti-
bodies (10% in the anti–Ang2-treated group vs 70% in control 
hIgG group) (Figure 4, A–C, lymph node weight: P = .020 [SCID, 
lower panel, Figure 4, C] to P = .043 [nu/nu, upper panel, Figure 4, 
C]). There was a clear trend of inhibition of the metastatic dissem-
ination of tumor cells into axillary lymph nodes of SCID mice as 
evaluated by the occurrence of metastasis (data not shown, 0/10 in 
Ang2-blocking group vs 4/10 in hIgG group) and the occurrence 
of cytokeratin-positive cells (Figure 4, D).
To evaluate whether Ang2 blockade affected homing of tumor 
cells into the lungs, luciferase-tagged LNM35 cells were injected 
intravenously into mice receiving the Ang-blocking antibody or 
hIgG and analyzed by the bioluminescent signal intensity from the 
excised lungs at 5 days. The anti-Ang2 antibody treatment 
decreased the metastatic burden in the lungs (Ang2-blocking anti-
body vs hIgG: 103.4 vs 225.6 photons/s/cm2/sr, n = 3 in both 
groups, two independent studies, difference = 122.2, 95% CI = 
38.4 to 206.0, P = .016; Figure 5, A and B). The metastatic foci in 
the lungs were also analyzed at 8 days after systemic inoculation of 
GFP-tagged tumor cells. The Ang2-blocking antibody inhibited 
lung metastasis formation statistically significantly (Ang2-blocking 
antibody [n = 4] vs hIgG [n = 3], 12.2 vs 22.4 LNM35 cell clusters 
per grid; difference = 10.2, 95% CI = 5.6 to 14.9, P = .002; Figure 
5, C and E). The inhibition of LNM35 lung metastasis by the 
Ang2-blocking antibody was also evident at the later time point of 
2 weeks (tumor area per grid in Ang2-blocking antibody vs hIgG 
groups, n = 4 in both groups: 14.78% vs 24.33%; difference = 9.55, 
95% CI = 3.12 to 15.98, P = .011; Figure 5, H left; and lung 
weight: Ang2-blocking antibody vs hIgG 0.22 vs 0.27 g, difference 
= 0.05 g, 95% CI = 0.01 to 0.09 g, P = .017, Figure 5, H right). In 
contrast, overexpression of Ang2 promoted tumor metastasis into 
the lungs when analyzed 4 days after inoculation of the GFP-
tagged LNM35 or LLC tumor cells (LLC cell cluster density in 
AdAng2 vs AdLacZ group, n = 4 in both groups, 35.7 vs 28.9, 
difference = 6.8, 95% CI = 1.7 to 12.0, P = .018; LNM35 cell clus-
ter density in AdAng2 vs AdLacZ group, n = 4 in both groups, 6.17 
Figure 4. Ang2-blocking antibodies inhibit lymphatic metastasis. A) 
Representative ex vivo bioluminescent images of the regional inguinal lymph 
nodes in nu/nu and SCID mice, excised at 16 days after subcutaneous tumor 
implantation, n = 8 and n = 10 in both groups, respectively. B) Quantification of 
bioluminescence emission from the regional lymph nodes. C) Occurrence 
of metastasis in regional lymph nodes, and lymph node weights, P = .020 to 
P = .043. D) Representative images of intranodal cytokeratin 7–positive immu-
nostaining in axillary lymph nodes excised from Ang2-blocking antibody and 
hIgG-treated nu/nu mice. Error bars = 95% confidence intervals. 
*P < .05. Anti-Ang2 = angiopoietin-2-blocking antibody; hIgG = human 
immunoglobulin G; p/s/cm2/sr = photons/s/cm2/steradian. Student’s t test. All 
statistical tests were two-sided. Scale bar in (A), 2 mm, in (D), 40 µm.
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Figure 5. Ang2 overexpression induces and Ang2-blocking antibodies 
suppress formation of metastatic foci in lungs. A) Bioluminescent 
images of lungs from Ang2-blocking antibody and hIgG control–treated 
NSG mice 5 days after systemic inoculation of luciferase- 
positive LNM35 cells. Two independent studies with similar results. B) 
Quantification of bioluminescent signal intensities, n = 3 in both 
groups, P = .016. C and D) Representative fluorescent micrographs of 
lung sections with foci of GFP-positive LNM35 metastatic cells at 8 days 
after intravenous inoculation of the cells into Ang2-blocking antibody 
vs hIgG-treated mice (C), and at 4 days after systemic inoculation into 
the tail vein of mice treated with AdAng2 or AdLacZ (D). E) Analysis of 
GFP-positive LNM35 foci and GFP signal area fraction in lung tissues of 
mice treated with Ang2-blocking antibodies or hIgG control, n = 4 in 
anti-Ang2 antibody group, n =3 in hIgG group. F) Quantification of the 
homing of intravenously injected GFP-positive LLC and LNM35 tumor 
cells into the lungs of AdAng2- or AdLacZ-treated mice, n = 4 in both 
groups, P = .019. G) Representative HE-stained lung sections with 
LNM35 metastatic foci analyzed 2 weeks after intravenous inoculation 
of the tumor cells to mice treated with Ang2-blocking antibodies vs 
hIgG. H) Quantification of metastatic area fraction in HE-stained sections 
and lung weights at excision, P = .028. Error bars = 95% confidence 
intervals. Scale bar in (A), 15 mm. Anti-Ang2 = angiopoietin-2-blocking 
antibody; GFP = green fluorescent protein; hIgG = human immunoglob-
ulin G; NSG = NOD SCID gamma; p = photons; p/s/cm2/sr = photons/
s/cm2/steradian. *P < .05. Student’s t test. All statistical tests were 
two-sided.
vs 2.67, difference = 3.50, 95% CI = 0.81 to 6.19, P = .019; Figure 
5, D and F).
Effects of Endothelial Ang2 Overexpression and Ang2-
Blocking Antibody on Vascular Integrity in Lung 
Metastases
To explain the effects of Ang2 overexpression and Ang2-blocking 
antibody on lung metastasis, we investigated their effects on the 
ultrastructure of the endothelial barrier. Endothelial cell–cell 
junctions and cell adhesion to the underlying basement membrane 
were analyzed by transmission electron microscopy in metastasis-
associated blood capillaries in the lung colonization assay in condi-
tional Ang2-overexpressing, Ang2-blocking antibody-treated and 
control mice. The metastasis-associated capillaries in the Ang2-
overexpressing mice showed more frequent and profound alter-
ations in capillary morphology compared with wild-type mice 
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(percent of analyzed capillaries, Ang2-overexpressing [n = 132] vs 
control mice [n = 130]: 66.5% vs 20.2%). These abnormalities in-
cluded endothelial cell detachment from the basement membrane 
(Ang2-overexpressing vs control mice: 49.6% vs 12.2%) and less 
extensive endothelial cell–cell junctions or even gaps between the 
endothelial cells (24.3% vs 8.1%) (Figure 6, A–D). The Ang2-
blocking antibodies reduced endothelial cell swelling and hetero-
geneity of metastasis-associated capillaries in the NSG mice and 
showed more prominent endothelial adherens junctions when 
compared with capillaries adjacent to the metastases in HSA con-
trol mice (Figure 6, E–H and Supplementary Figure 4, available 
online).
Influence of Ang2-Blocking Antibody on Postnatal Retinal 
Angiogenesis
Neonatal retinal angiogenesis is dependent on Ang2 expression 
(12), and blocking Ang2 has been found to inhibit retinal angiogen-
esis (27). To further investigate the role of Ang2 during physiolog-
ical retinal angiogenesis, we injected Ang2-blocking or control 
antibodies to newborn NMRI pups during postnatal days P0–P4. 
In line with results from a parallel independent study (27), we 
observed a statistically significant decrease in retinal vascularization 
in the Ang2-blocking antibody-treated pups when compared with 
the control group. In addition, we found decreased branching den-
sity (Supplementary Figure 5, A and B, available online) and vascu-
lar tuft-like structures located at the edge of the advancing vessel 
network (Supplementary Figure 5, A, available online) in the Ang2-
blocking antibody-treated pups Tie2 was expressed in the retinal 
vessels, except for the tip cells. However, reduced Tie2 staining was 
detected in the angiogenic front of anti-Ang2 antibody treated 
pups, whereas the expression of the receptor in the rest of the retina 
was not altered (Supplementary Figure 5, C, available online). 
High-resolution imaging of the retinas treated with Ang2-blocking 
antibody revealed isolated patterns of pericytes that were not asso-
ciated with endothelial cells (Supplementary Figure 5, D and E, 
available online), suggestive of vessel regression or failed sprouts.
The Effect of Blocking Ang2 Antibodies on Ligand-Induced 
Cellular Trafficking of the Tie2 Receptor
To study the cellular mechanisms responsible for the in vivo effects 
of the Ang2-blocking antibody, we analyzed its effects on cultured 
microvascular endothelial cells. Our previous results (30) and those 
of Fukuhara et al. (38) have recently shown that Ang1 induces a 
distinct Tie2 signaling complex at endothelial cell–cell contacts, 
where it provides survival and stability signals and induces phos-
phorylation of the endothelial nitric oxide synthetase (eNOS) 
(30,38). In the previous report, Ang2 was found to compete with 
Ang1 for receptor binding at the cell–cell junctions (30). To eluci-
date the effects of the Ang2-blocking antibodies on this process, 
endothelial cells expressing Tie2 fluorescently tagged with GFP 
were treated with the Ang2-blocking or control antibodies. In mi-
crovascular lymphatic and blood vascular endothelial cells, which 
produce Ang2 in culture (39), Tie2 and Ang2 were localized at the 
cell–cell junctions (Figure 7, A and B). However, autocrine Ang2 
induced only weak Tie2 phosphorylation and almost no eNOS 
phosphorylation when compared with exogenously provided Ang1 
(Figure 7, A, Supplementary Figure 6, A, available online).
Figure 6. Effect of Ang2-blocking antibodies on endothelial cell–cell 
junctions in lung metastases and Ang2 overexpression on vascular integ-
rity. Transmission electron micrographs (TEM) of capillaries adjacent to 
metastatic B16-F10 melanoma cell (MC) colonies of Ang2-overexpressing 
(A and B) and control C57Bl/6J mice (C and D). TEM micrographs of 
Ang2-blocking antibody (E and F) and HSA-treated (G and H) metastases 
of NSG mice, samples from at least three mice were evaluated. (B), (D), 
(F), and (H) show the boxed areas at a higher magnification. Note that in 
the Ang2-overexpressing mice, the capillaries show more structural 
abnormalities in endothelial cell (EC), basement membrane (BM) adhe-
sions and less extensive endothelial cell–cell junctions (arrows in B and 
D) than in the control mice. Arrowheads in (B) and (D) indicate the 
interface between the ECs and the BM. Note also that the Ang2-blocking 
antibody treatment has a normalizing effect; the endothelium in the 
HSA-treated lung metastasis has less prominent (stars) junctional 
complexes (arrows) and uneven EC layering. Scale bar in (A), (C), (E), 
and (G), 1 µm; in (B), (D), (F), and (H), 500 nm. Anti-Ang2 = angiopoietin-
2-blocking antibody; HSA = human serum albumin; NSG = NOD SCID 
gamma; RBC = red blood cell; VEC-tTA/Tet-OS-Ang2 = VE-cadherin-tTA/
Tet-OS-Ang2 transgenic mouse.
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The Ang2-blocking antibody induced internalization of Ang2, 
leading to decreased Tie2 and Tie1 receptor localization and Tie2 
phosphorylation at the endothelial cell–cell contacts (Figures 7, A 
and B and 8 and Supplementary Figure 7, available online). In 
contrast, the Ang2-blocking antibody did not inhibit Ang1-
stimulated Tie2 localization and phosphorylation at cell–cell contacts, 
indicating specific blockade of only the Ang2 signals (Figure 7, A). 
Internalized vesicles containing Ang2 were observed at 30 minutes 
of treatment with Ang2-blocking antibodies, but after 5 hours, 
they were no longer visible (Figure 8). Decreased formation of 
Figure 7. Ang2-blocking antibody inhibits the formation of Ang2-induced 
Tie2 signaling complexes. A) Human dermal microvascular lymphatic 
endothelial cells (LECs) were transfected with the Tie2-GFP retrovirus. 
The cells were treated with Ang2-blocking antibody (48 hours) or left 
untreated, followed by stimulation with COMP-Ang1 (30 minutes). The 
cells were fixed, permeabilized, and stained for Ang2 and phosphory-
lated Tie2 (P-Tie2). Note that the Ang2-blocking antibody inhibits Tie2 
translocation induced by endogenous Ang2 but not by exogenous 
COMP-Ang1 added to the cultures. B) Blood vascular endothelial cells 
(BECs) were transfected with Tie2-GFP and treated for 30 minutes  
with Ang2-blocking antibody or hIgG as a control. The cells were fixed, 
permeabilized, and stained for VE-cadherin or Ang2. The Ang2-blocking 
antibody inhibits Ang2-induced Tie2 translocation also in the BECs. 
Nuclear DAPI stain. Confocal images. Scale bar, 20 µm. Anti-Ang2 = 
angiopoietin-2-blocking antibody; COMP-Ang1 = cartilage oligomeric 
matrix protein–angiopoietin-1; hIgG = human immunoglobulin G.
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Figure 8. Ang2-blocking antibody induces internalization of the Ang2-
Tie2 complexes. BECs transfected with Tie2-GFP retrovirus were 
treated with Ang2-blocking or hIgG control antibody for the indicated 
periods. The cells were fixed, permeabilized, and stained for Ang2. 
Note that the Ang2-blocking antibody, but not control antibody, 
induces transient internalization of Ang2 and Tie2 in intracellular 
vesicles, evident at 30 minutes, whereas no vesicles are present at 
5 hours after Ang2-blocking antibody treatment. Nuclear DAPI stain. 
Confocal images. Scale bar, 20 µm. Ang2 = Angiopoietin-2-detecting 
antibody; Anti-Ang2 = angiopoietin-2-blocking antibody; BEC = 
blood microvascular endothelial cells; hIgG = human immunoglob-
ulin G.
Ang2-Tie2 complexes was also detected following transfection of 
Tie2-GFP expressing cells with siRNA oligonucleotides to silence 
Ang2 expression (Supplementary Figure 6, B, available online).
We further analyzed the internalization of cell surface–bound 
anti-Ang2 antibody in LECs. To this end, the anti-Ang2 anti-
bodies were incubated with cells on ice and either directly sub-
jected to glycine wash for depletion of the cell surface or incubated 
at 37°C to allow internalization of cell surface bound antibodies. 
The acid wash completely removed cell surface–bound antibodies 
(0% remained from maximal binding), but the internalized anti-
bodies were retained in the cells (11% remained from maximal 
binding, Supplementary Figure 8, available online). These data 
indicate that the anti-Ang2 antibody is partially internalized into 
LECs in vitro.
To investigate the effect of tumor cells on Ang2-induced 
Tie2 signaling, we cultured Tie2-GFP expressing blood vascu-
lar endothelial cells on Transwell filters in the presence or 
absence of the LNM35 lung carcinoma cells in the lower com-
partment. Notably, Ang2-Tie2 complexes were increased in the 
endothelial cell junctions in the presence of the LNM35 tumor 
cells, whereas complex formation was blocked by the Ang2-
blocking antibodies (Supplementary Figure 9, available online). 
These results suggest that the Ang2-blocking antibodies are 
associated with decreased expression of Ang2-Tie2 complexes 
while leaving Ang1-Tie2 complexes intact at endothelial cell–
cell junctions.
Discussion
Our results indicate that Ang2 increases tumor metastasis at least 
in part by promoting endothelial disruption and increasing tumor 
cell translocation and homing to target organs. We also provide 
mechanistic insight into the effects of the antibody-mediated 
blockade of Ang2 at the cellular level. To address the function of 
Ang2 in tumor metastasis, we used systemic and endothelial cell-
specific Ang2 overexpression, as well as Ang2-blocking antibodies 
in various tumor models. Our results demonstrate that systemic 
Ang2 overexpression promotes tumor lymphangiogenesis as well 
as lymph node and lung metastasis in addition to tumor growth 
and angiogenesis. Ang2 also enhanced the establishment of meta-
static colonies in the lungs after intravenous tumor cell inocula-
tion. Importantly, by using VEC-tTA/Tet-OS-Ang2 transgenic 
mice, in which Ang2 is specifically induced only in the vascular 
endothelium, we demonstrated that endothelial overexpression of 
Ang2 increases lung metastasis. Alternatively, Ang2 blockade atten-
uated tumor lymphangiogenesis, dissemination of tumor cells via 
the lymphatic vessels, lung metastasis, and tumor cell colonization 
of the lungs.
The antiangiogenic effects of specific Ang2 blockade on tumor 
growth and vascularization have been previously characterized 
using Ang2 blocking in various tumor xenografts, but the effects 
on tumor metastasis were not investigated (16,18,19,27). In one 
report, intrapleural injection of lentiviral Ang2 short hairpin 
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RNA in mice bearing mammary tumor xenografts was reported to 
inhibition endothelial permeability in the lungs (40). In another 
report, Ang2 overexpression in tumor cells increased their invasive 
properties by an autocrine, Tie2-independent effect mediated via 
the integrins (9). However, only a minor fraction of human tumor 
cell lines express detectable amounts of Ang2 (1). Importantly, the 
lung cancer cells we used expressed no detectable Ang2 in culture, 
unlike in previous studies in which Ang2 inhibitors were used 
(16,41).
Targeted deletion of Ang2 leads to defective blood vessel develop-
ment in the eye and lymphatic vessel development in the mesente-
rium and skin (12). In the developing postnatal retina, the 
Ang2-blocking antibody was found to delay vascularization (27), 
which was confirmed in our study. Further analysis showed that 
blocking Ang2 induced vascular tuft-like structures at the angiogenic 
front, where signs of sporadic sprout regression were observed. In the 
primary tumors treated with the Ang2-blocking antibody, basement 
membrane and pericyte marker–positive and endothelial cell negative 
vessel structures were present, similarly indicating endothelial regres-
sion. These results are consistent with the data that autocrine Ang2 
contributes to endothelial cell survival and migration in some con-
texts (10,42, our unpublished results using Ang2-blocking antibody). 
In mice surviving Ang2 deletion, an initial delay was observed in the 
growth of isogenic tumors (17); however, in our study, the Ang2-
blocking antibodies also induced statistically significant inhibition in 
the later phases of tumor growth. Thus, it is possible that genetic 
deletion of Ang2 and blocking antibodies against Ang2 have different 
mechanisms of action.
We (30) and Fukuhara et al. (38) have previously shown that 
angiopoietins induce the formation of unique Tie2 receptor 
complexes in endothelial cells (30,38). In cells with established 
contacts to other cells, Ang1 and Ang2 were found to trigger Tie2 
translocation to cell–cell junctions, where Ang1 has been shown to 
reduce paracellular permeability (30,38,43). Here, we show that 
autocrine Ang2 secreted by endothelial cells similarly induces Tie2 
and Tie1 translocation to cell–cell contacts. However, in contrast 
to Ang1, Ang2 induced only weak Tie2 phosphorylation and may 
thus decrease Ang1 signals via the Tie receptors in the endothelial 
cell–cell junctions (30). When the endothelial cells were cocul-
tured with the tumor cells, the presence of Ang2-Tie2 complexes 
was increased in the endothelial cell–cell junctions, even when the 
cells were under normal oxygen pressure. The Ang2-blocking 
antibody inhibited endothelial Ang2 function by inducing the in-
ternalization of the Ang2-Tie2 receptor complexes and by inhibit-
ing the subsequent formation of such complexes. Because of the 
multimeric nature of Ang2, the anti-Ang2 antibody may result in 
the formation of large receptor clusters on the cell surface; these 
could be more effectively targeted for endocytosis. The Ang1-
induced Tie receptor complexes were not affected by the Ang2 
antibody. Because only the Ang2-bound Tie2 receptor fraction 
was directed for internalization, the results suggest that during 
Ang2 blocking in the metastatic lungs, Ang1 can bind and activate 
Tie2, contributing to stabilization of endothelial cell–cell junctions.
Our results showed that fewer tumor cell colonies were established 
in the lungs of mice treated with the Ang2-blocking antibody when 
compared with control antibody–treated mice at the relatively 
early time points when angiogenesis was not yet detected in the 
metastatic foci. Although we have not imaged extravasation per se, 
these results suggest that blocking Ang2 inhibited the extravasa-
tion of tumor cells to the lungs or the very early stages of meta-
static colony establishment. It was previously shown that the 
tumor cell–associated lung capillaries express increased amounts of 
Ang2 (15). In the pulmonary vessels associated with the lung 
metastases, the Ang2-blocking antibody seemed to counteract the 
disruption of the endothelial cell–cell junctions and vascular integ-
rity, suggesting that by decreasing cell–cell adhesion and endothe-
lial integrity, endogenous Ang2 can facilitate the extravasation step 
at the endothelial cell–cell junctions. How Ang2 leads to the dis-
ruption of endothelial integrity remains to be elucidated. Such a 
mechanism may involve binding to integrins and loss of EC-EC 
junctional complexes, as reported for the related angiopoietin-like 
4 (Angptl4) protein (44).
Although we show that the Ang2-blocking antibodies inhibit 
metastasis in immunodeficient mice in the absence of inflamma-
tory cell contribution, Ang2 also affects the inflammatory and 
immune responses in tumors (45,46). Ang2 has been reported to 
stimulate Tie2-expressing monocytes to suppress T-cell activa-
tion and to promote regulatory T-cell expansion (45). In tumor-
bearing immunocompetent mice, Ang2-blocking antibodies 
interfered with Tie2 expression in a subpopulation of macrophages 
and decreased angiogenesis, resulting in inhibition of metastasis 
(46). We found that the disruption of endothelial cell–cell and 
cell–matrix contacts in metastatic pulmonary capillaries was 
further aggravated in an immunocompetent background, sug-
gesting that the immune response can contribute to endothelial 
destabilization.
This study had some limitations. We used rapidly growing 
tumors. Thus, the conclusions may be strengthened with the use 
of genetically engineered mouse tumor models. The dose–response 
range was not evaluated, and because of the rapid tumor growth 
and treatment schedules, possible adverse effects related to the 
treatment may have gone unnoticed. In addition, it remains to be 
investigated if the Ang2 antibodies can inhibit metastatic colonization 
of other tissues besides the lungs.
Our results are in line with the previously proposed model in 
which Ang2 becomes initially overexpressed in the tumor co-opted 
blood vessels, leading to vessel destabilization. This increases hyp-
oxia in the tumor, and the expression of hypoxia-regulated VEGF 
and Ang2 growth factors, inducing robust tumor angiogenesis 
(47). The results from a study in which Ang2 was ectopically 
expressed in a mammary carcinoma cell line also support a model 
of dual action of Ang2 in the tumors (48). In that study, Ang2 expres-
sion induced intratumoral hemorrhage, non-functional and abnor-
mal blood vessels, and was associated with pericyte loss and 
increased endothelial cell apoptosis, possibly because of imbalance 
of the Ang2 and VEGF levels in the tumors (48). It has been 
claimed that VEGFR2-targeted anti-angiogenic therapy increases 
metastatic frequency in some preclinical animal models (49). Our 
results showing that Ang2 induces vascular destabilization during 
tumor metastasis suggest that during VEGF blockade, Ang2-
induced vascular destabilization could be associated with increased 
metastasis. Thus, combinatory therapy blocking both VEGF and 
Ang2 may provide more effective tumor growth and metastasis 
inhibition. 
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In conclusion, we show that Ang2 contributes substantially to 
tumor progression and that blocking of Ang2 inhibits endothelial 
destabilization and constitutes an efficient strategy for inhibition of 
tumor growth and metastatic dissemination. Our data thus provide 
important new insights into the Ang2/Tie2 signaling pathway as an 
attractive target for cancer therapy.
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